BioNTech SE · BNTX · Next earnings

BioNTech SE reports Tuesday, Nov 3, 2026

BNTX reports before market open with consensus EPS at $0.85 and revenue at $1.17B. Last quarter: BioNTech raises 2026 revenue outlook as oncology pipeline advances

Reports Before market open0 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $0.85 Calendar consensus
Consensus revenue $1.17B Calendar consensus
Report date Nov 3, 2026 Tuesday, date estimated
Session Before market open 0 days away

Where BNTX left off: FY2026 Q3

Full report

BioNTech raises 2026 revenue outlook as oncology pipeline advances

EPS surprise — Reported — vs $0.85
Revenue surprise — Reported — vs $1.17B
Stock move -0.7% Event window
Subsequent drift 0.0% Up to 20 sessions

Management raised full-year 2026 revenue guidance to €1.7–1.9 billion, according to the current-quarter analysis. The prior-quarter analysis had described guidance as lowered, with a €1.6–1.9 billion range.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • COVID vaccine sales remain a source of near-term revenue pressure.
  • Clinical readouts and regulatory pathways for late-stage oncology assets remain uncertain.
  • T-Pam safety concerns, including interstitial lung disease signals, require attention.
  • Management’s plans across multiple modalities and partnerships require execution.

Questions analysts left open

  • Timing and magnitude of the first interim analysis for gotistobart.
  • Regulatory path and FDA engagement for gotistobart and other assets.
  • Whether Chinese trial findings translate to global populations, and how new leadership prioritizes mRNA versus other modalities.

Ask FN2 about BNTX next report

Transcript, numbers and history already loaded
What should I watch for in BNTX's next earnings report?How did BNTX guide last quarter, and is consensus above or below that?Give me the bull and bear case going into BNTX earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the BNTX recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent BNTX quarters

All BNTX earnings
-0.7%FY2026 Q3

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.